TCGA-LC-A66R-01A-41R-A30C-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 15.3088042
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.620
- INTERFERON_ALPHA_RESPONSE+0.550
- G2M_CHECKPOINT+0.510
- INTERFERON_GAMMA_RESPONSE+0.510
- INFLAMMATORY_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.490
- TNFA_SIGNALING_VIA_NFKB+0.470
- MITOTIC_SPINDLE+0.450
- IL6_JAK_STAT3_SIGNALING+0.420
- MYC_TARGETS_V1+0.370
Top 10 suppressed
- ADIPOGENESIS-0.190
- CHOLESTEROL_HOMEOSTASIS-0.180
- FATTY_ACID_METABOLISM-0.180
- PEROXISOME-0.180
- BILE_ACID_METABOLISM-0.150
- XENOBIOTIC_METABOLISM-0.130
- PANCREAS_BETA_CELLS-0.100
- TGF_BETA_SIGNALING-0.090
- MYOGENESIS-0.050
- UV_RESPONSE_DN-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CR-7373-01A-11R-2016-07 | — | — | 0.909 |
| 2 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.902 |
| 3 | TCGA-XF-A9SM-01A-11R-A42T-07 | — | — | 0.884 |
| 4 | TCGA-OR-A5JB-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.880 |
| 5 | TCGA-XF-AAN5-01A-11R-A42T-07 | — | — | 0.879 |
| 6 | TCGA-XF-A9SY-01A-21R-A42T-07 | — | — | 0.874 |
| 7 | R214 | — | — | 0.873 |
| 8 | SRR1516056 | — | — | 0.871 |
| 9 | TCGA-56-8201-01A-11R-2247-07 | — | cohortA1 | 0.868 |
| 10 | TCGA-ZF-AA58-01A-12R-A42T-07 | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.510 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.470 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.450 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |